Table 3.
Myelo- and lymphoproliferative cancers SIRs
| Overall |
Males |
Females |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total follow-up, pyrs | 13 315 | 3732 | 9584 | |||||||||
| Cancer site and ICD-10 code | O | Rate per 100 pyrs (95% CI) | E | SIR (95% CI) | O | Rate per 100 pyrs (95% CI) | E | SIR (95% CI) | O | Rate per 100 pyrs (95% CI) | E | SIR (95% CI) |
| Myelo- and lymphoproliferative C81–C96 | 26 | 0.20 (0.13, 0.29) | 10.72 | 2.43 (1.58, 3.55) | 9 | 0.24 (0.11, 0.46) | 4.23 | 2.13 (0.97, 4.04) | 17 | 0.18 (0.10, 0.28) | 6.49 | 2.61 (1.53, 4.19) |
| Myelo- and lymphoproliferative C81–C96 England only | 25 | 0.22 (0.14, 0.33) | 9.16 | 2.73 (1.77, 4.03) | 9 | 0.28 (0.13, 0.53) | 3.73 | 2.42 (1.10, 4.59) | 16 | 0.20 (0.12, 0.33) | 5.43 | 2.95 (1.68, 4.78) |
| Lymphoma C81–85 | 21 | 0.16 (0.10, 0.24) | 5.51 | 3.81 (2.36, 5.82) | 8 | 0.21 (0.09, 0.42) | 2.02 | 3.95 (1.71, 7.79) | 13 | 0.14 (0.07, 0.23) | 3.49 | 3.73 (1.98, 6.37) |
| Hodgkin lymphoma C81 | 5 | 0.04 (0.01, 0.09) | 0.39 | 12.82 (4.16, 29.92) | NR | NR | NR | NR | NR | NR | NR | NR |
| NHL C82–85 | 16 | 0.12 (0.07, 0.20) | 5.12 | 3.12 (1.79, 5.07) | 5 | 0.13 (0.4, 0.31) | 1.88 | 2.66 (0.86, 6.21) | 11 | 0.11 (0.06, 0.21) | 3.24 | 3.39 (1.69, 6.07) |
O: observed; E: expected; NR: not reported (fewer than five observed or expected cancers).